JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline
Bruce Cozadd, the retiring CEO of Jazz Pharmaceuticals, has outlined a developing oncology pipeline at the company. Speaking at the…
Oncology
-
-
First patient dosed as Marengo’s invikafusp alfa trial expands to Europe
Clinical-stage biotechnology company Marengo Therapeutics has announced that it has dosed the first patient in Phase II of its STARt-001…
-
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy
iTeos Therapeutics has announced that it has “deprioritised” inupadenant for the treatment of non-small cell lung cancer (NSCLC), following disappointing…
-
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription
US-based clinical-stage biotechnology company Cardiff Oncology has announced positive initial data from its randomised Phase II clinical trial evaluating onvansertib…
-
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
Merus’ Bizengri (zenocutuzumab-zbco) has received accelerated approval from the US Food and Drug Administration (FDA), marking “an important milestone” in…
-
‘Pill-on-a-thread’ cancer screening trial commences with first patients
A pivotal investigator-led clinical trial for a new ‘pill-on-a-thread’ innovation for oesophageal cancer screening has welcomed its first patients, Cambridge…
-
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
Lyell Immunopharma has entered a definitive agreement to acquire ImmPACT Bio, a privately-owned clinical-stage biotechnology company specialising in chimeric antigen…
-
Black women in the US impacted more by breast cancer
Advancements in technology and medical knowledge have improved early breast cancer detection and treatment. But despite these advances, breast cancer…
-
Avistone Met inhibitor Phase I trial cleared for sites in Canada
Beijing Avistone Biotechnology’s Phase I trial evaluating its candidate for mesenchymal epithelial transition (MET) alteration solid tumour treatment has been…
-
Keytruda keys in on survival: Promising results in high-risk early-stage TNBC from KEYNOTE-522
At the European Society for Medical Oncology Congress on September 13–17, promising results from the Phase III KEYNOTE-522 study involving…
